Fig. 5.

Combination of IT with CTLA-4 blockade does not negatively impact toxicities. Mice (n = 3–4 mice/group) were treated with control (rIgG/PBS) or IT (40/2) with either hamster IgG (hmIgG) or anti-CTLA-4 (UC10) as per the regimen in 2A and evaluated for a weight loss and b serum ALT in treatment groups. c–d Hematoxylin and eosin stained c liver (2×) and d gut (4×) sections from all treatment groups were evaluated based on criteria described in detail in Methods section. Quantification of pathology scores from e day 11 and f day 18 is shown. For liver and gut sections, scale bars indicate 2 mm and 600 μm, respectively. Data are representative of 3 independent experiments. Statistical analysis was performed using one- or two-way ANOVA where appropriate with Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001